Skip to main content
Article thumbnail
Location of Repository

Risperidone in the treatment of bipolar mania

By Martha Sajatovic, Madhusoodanan Subramoniam and Matthew A Fuller


Atypical antipsychotic medications have assumed growing importance for the treatment of bipolar disorder, an illness that affects approximately 1.2%–3.7% of the general population in a given year. Current practice guidelines for the treatment of bipolar mania support the use of atypical antipsychotic medications as monotherapy or as a component of polytherapy, and in clinical settings the use of atypical antipsychotics to treat bipolar disorder is widespread. Risperidone is an atypical antipsychotic, sometimes referred to as a second-generation antipsychotic. The receptor-binding profile of risperidone, which includes potent antagonism of the serotonin 5-HT2A, dopamine D2, and alpha-adrenergic receptors, is believed to be related to positive effects on mood. The FDA-approved bipolar indications for risperidone include: 1) monotherapy for short-term treatment of acute manic or mixed episodes associated with bipolar I disorder and 2) combination therapy with lithium or valproate for the short-term treatment of acute manic or mixed episodes associated with bipolar I disorder. This review of risperidone for bipolar mania will address the chemistry, pharmacodynamics, pharmacokinetics, and metabolism of risperidone, use with concomitant medications, clinical trials in bipolar mania, as well as safety and tolerability issues. Finally, dosing and administration are addressed as well as use for bipolar mania in geriatric, child, or adolescent patients

Topics: Expert Opinion
Publisher: Dove Medical Press
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2004). Diabetes Association; America Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity,
  2. (2002). Psychiatric Association.
  3. (2004). Risperidone in combination with mood stabilizers for acute mania: a multicenter, open study. Int Clin Psychopharmacol,
  4. (2003). Open-label study of risperidone in children with bipolar disorder. Presented at the 16th annual meeting of the European Neuropsychopharmacology Congress [abstract].
  5. (2004). Risperidone in combination with mood stabilizers: a 10-week continuation phase study in bipolar I disorder.
  6. (2005). A randomized,doubleblind , placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression.
  7. (2005). and Drug Administration Center for Drug Evaluation and Research.
  8. (2005). Risperidone: a review of its use in the treatment of bipolar mania.
  9. (1999). Risperidone treatment for juvenile bipolar disorder: a retrospective chart review.
  10. (2005). Drug information handbook for psychiatry.
  11. (2004). Long-term observational comparison of risperidone and olanzapine in bipolar disorder. Ann Clin Psychiatry,
  12. (2005). Symptomatic remission in patients with bipolar mania: results from a double-blind, placebocontrolled trial of risperidone monotherapy.
  13. (2000). A naturalistic comparison of clozapine, risperidone and olanzapine in the treatment of bipolar disorder.
  14. (2004). Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double blind, placebo-controlled trial.
  15. (2003). Screening for bipolar disorder in the community.
  16. (2003). 2003a. Risperdal® (Consta®) product information
  17. Pharmaceuticals 2003b. Risperidone (Risperdal®) product information.
  18. (2003). alpha-adrenoreceptor blockade by clozapine and other antipsychotic drugs.
  19. (2004). The Expert Consensus Guideline Series: Treatment of Bipolar Disorder
  20. (2003). Risperidone monotherapy in acute bipolar mania [poster].
  21. (2005). Risperidone in the treatment of acute mania: double-blind, placebo-controlled study.
  22. (2004). Demographic and diagnostic characteristics of the first 1000 patients enrolled in the systematic treatment enhancement program for bipolar disorder (STEP BD).
  23. (2005). 6:460–9.Neuropsychiatric Disease and Treatment 2006:2(2) 138 Sajatovic et al Kowatch
  24. (1994). Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity.
  25. (2001). Fixed-dose risperidone in mania: an open experimental trial.
  26. (2003). Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
  27. (2004). The antidepressant effects of risperidone and olanzapine in bipolar disorder.
  28. (2002). Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia.
  29. (2002). Dopaminergic deficit and mood disorders. Int Clin Psychopharmacol, 17(Suppl 4):S1–7.
  30. (2004). Risperidone versus olanzapine as adjunctive therapy in the treatment of patients with bipolar disorder who are receiving a primary thymoleptic agent. American Psychiatric Association 157th Annual Meeting.
  31. (1993). The de facto mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatr,
  32. (2002). Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety.
  33. (2004). Strategies for improving treatment of bipolar disorder: integration of measurement and management.
  34. (2005). Risperidone for bipolar disorders. Expert Rev Neurother,
  35. (1996). Outcomes of risperidone therapy for elderly patients with chronic psychosis.
  36. (1998). Risperidone compared with both lithium and haloperidol in mania: A double-blind, randomized controlled trial. Clin Neuropharmacol,
  37. (2004). Risperidone and paroxetine given singly and in combination for bipolar depression.
  38. (2005). Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebocontrolled trial followed by a 9-week double-blind trial of risperidone and haloperidol.
  39. (2001). Risperidone with and without paroxetine compared with paroxetine alone for bipolar depression. 41st Annual meeting of the American College of Neuropsychopharmacology (ACNP).
  40. (2004). Acute and continuation risperidone monotherapy in mania. Hum Psychopharmacol,
  41. (2002). Risperidone in the treatment of mania: efficacy and safety results from a large, multicentre, open study in Spain.
  42. (2003). Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomized controlled trial.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.